Furthermore, carbonic anhydrase IX (CAIX)-targeted CAR-T cell therapy in renal cell carcinoma trials resulted in liver enzyme abnormalities due to CAR-T cell infiltration in the bile duct epithelium expressing CAIX. This evidence concerns the gene CA9 and renal cell carcinoma.